NCT01933802View on ClinicalTrials.gov

Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

March 31, 2017

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

intrathecal administration of autologous MSC-NP

Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.

Trial Locations (1)

10019

Tisch MS Research Center of New York, New York

All Listed Sponsors
lead

Tisch Multiple Sclerosis Research Center of New York

OTHER

NCT01933802 - Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis | Biotech Hunter | Biotech Hunter